Date,Sentence,Prediction,sentimentScore
2007-01-12,Employment contracts have been blamed for virtually guaranteeing huge payouts even when an executive fails.,negative,-0.7974504232406616
2007-01-12,"Hire by the Contract Now, Risk a Big Regret Later",negative,-0.5603632926940918
2007-01-22,The world’s largest drugmaker is seeking to cut costs by up to $2 billion a year amid fierce competition.,positive,0.49859946966171265
2007-01-22,"Pfizer to Lay Off 10,000 Workers",negative,-0.9465305209159851
2007-01-23,"Pfizer will reorganize its businesses and close several manufacturing and research sites, including a plant in Brooklyn, the borough where the drug company began.",neutral,-0.17177319526672363
2007-01-23,"Pfizer, Hurt by Rival Drugs, Will Lay Off 7,800",negative,-0.9555290937423706
2007-01-23,"Pfizer is phasing out its manufacturing plant in Brooklyn, on the same Flushing Avenue site where the company was founded in 1849.",neutral,-0.04765135049819946
2007-01-23,Shutting Doors Where a Drug-Making Giant Began,negative,-0.4016973674297333
2007-01-27,That era when Pfizer was the king of the hill wasn’t some distant age — it was just maybe three or four years ago.,neutral,-0.020935043692588806
2007-01-27,"Oh, how the mighty have fallen!",neutral,0.16933554410934448
2007-01-27,The Dangers of Swinging for the Fences,neutral,-0.16705331206321716
2007-02-02,Pfizer is acquiring a small Pennsylvania start-up developing experimental treatments for Type 2 diabetes.,neutral,0.28637978434562683
2007-02-02,"Pfizer said yesterday that it would buy BioRexis Pharmaceutical, which has 50 employees and two key drug compounds in early testing, for an undisclosed amount.",neutral,0.06811397522687912
2007-02-02,Pfizer Buys Experimental Drug Start-Up,neutral,0.1269465833902359
2007-03-21,"Pfizer, the drug maker, won a court ruling yesterday blocking a rival company, Teva Pharmaceutical Industries, from marketing a generic version of the painkiller Celebrex, the world’s top-selling arthritis drug, until 2015.",negative,-0.8848924040794373
2007-03-21,Pfizer Painkiller’s Patent Upheld,neutral,0.004663962870836258
2007-04-10,"Wall Street analysts are cutting their sales estimates for Exubera, which has been dogged by questions about its safety, cost and convenience.",negative,-0.9577016234397888
2007-04-10,Pfizer Drug for Diabetes Is Lagging,neutral,-0.19126561284065247
2007-04-10,A consumer group has asked the F.D.A.,neutral,-0.0038377568125724792
2007-04-10,"to ban the long and unconventional ad, saying it gives a false impression.",negative,-0.8628140687942505
2007-04-10,Celebrex Commercial Draws Criticism,neutral,0.031460922211408615
2007-04-30,"Pfizer has always straddled a line marketing Viagra, insisting that the drug treats a serious medical condition while promoting it with wink-and-a-nod ads.",neutral,-0.13218753039836884
2007-04-30,Minky Viagra?,negative,-0.3956671357154846
2007-04-30,"Pfizer Doesn’t Want You to Understand It, Just Buy It",neutral,-0.019533758983016014
2007-05-21,"John L. LaMattina said he was leaving the company, five months after Pfizer was forced to cancel development of its highest-profile drug candidate.",negative,-0.8041360378265381
2007-05-21,Pfizer’s Head of Research Is Departing,neutral,0.00902407243847847
2007-07-06,"Pfizer settled a lawsuit against a rival drug maker, Novartis, for alleged infringement of a United States patent for the antibiotic medicine Zithromax.",negative,-0.9053565263748169
2007-07-06,"Pfizer sued Novartis and Sandoz, a unit operating in the United States, in February 2006 in federal court in Wilmington, Del., saying it would be irreparably harmed by the rival companies’ use of the invention for forms of crystal azithromycin; Pfizer sought unspecified damages.",negative,-0.8871867060661316
2007-07-06,"The parties have agreed to settle all claims over the 2005 drug patent, and the suit was dismissed June 25, according to court papers.",neutral,0.0018759295344352722
2007-07-06,"Pfizer is based in New York, and Novartis is based in Basel, Switzerland.",neutral,0.0034984108060598373
2007-07-06,Switzerland: Drug Suit Settled,negative,-0.8879400491714478
2007-07-14,Drug makers are exploring the possibility of tying pharmaceutical prices to performance.,neutral,0.03792065754532814
2007-07-14,Pricing Pills by the Results,neutral,0.012103565037250519
2007-07-16,"COMPANY REPORTS Earnings season gets into full swing, particularly for technology, financial and drug companies.",positive,0.8325868844985962
2007-07-16,"Reports will come from Charles Schwab and Mattel (Monday); Coca-Cola, I.B.M., Intel, Johnson & Johnson, Merrill Lynch, Novartis, Wells Fargo and Yahoo (Tuesday); Abbott Laboratories, Altria, AMR, Delta Air Lines, eBay, JPMorgan Chase, Pfizer, Southwest Airlines and United Technologies (Wednesday); Advanced Micro Devices, Bank of America, Bank of New York Mellon, Continental Airlines, Dow Jones, First Data, Google, Honeywell, Microsoft, Motorola and Wyeth (Thursday); and Boston Scientific, Caterpillar and Citigroup (Friday).",neutral,0.003950260579586029
2007-07-16,Looking Ahead,neutral,0.013165891170501709
2007-10-05,The hirings are aimed at rejuvenating the drug maker’s lagging research operations.,positive,0.7632231116294861
2007-10-05,Pfizer Hires 2 Top Scientists to Expand Drug Pipeline,positive,0.5882126688957214
2007-10-13,"Pfizer’s most recent compensation report, the basis for an attempt to revamp the format of such reports, is now under S.E.C.",neutral,0.03402461111545563
2007-10-13,review for inadequate disclosure.,negative,-0.68108069896698
2007-10-13,Pfizer’s Attempt at Financial Clarity Gets Blurred,neutral,-0.002272680401802063
2007-10-18,"Pfizer will take a charge of $2.8 billion for costs associated with Exubera, making it one of the most expensive flops in the history of the pharmaceutical industry.",negative,-0.4783153831958771
2007-10-18,Weak Sales Prompt Pfizer to Cancel Diabetes Drug,negative,-0.9425153136253357
2007-10-19,"The discontinuation of Exubera, an inhaled insulin, is another black eye for Pfizer, the world’s biggest drug company, which has recently sustained a series of reversals.",negative,-0.8989011645317078
2007-10-19,Weak Sales Prompt Pfizer to Cancel Diabetes Drug,negative,-0.9425153136253357
2007-11-03,"Many patients on the cholesterol drug are switching to a cheaper alternative, but Pfizer is not letting its flagship product go down without a fight.",neutral,-0.14273983240127563
2007-11-03,Maker of Lipitor Digs in to Fight Generic Rival,negative,-0.5293532013893127
2007-11-05,"Drugs to raise so-called good cholesterol may still have a future despite the failure last year of an experimental treatment from Pfizer, researchers said.",positive,0.61346036195755
2007-11-05,Hunt for Cholesterol Drug Is Not Over,neutral,0.04379262775182724
2007-11-16,Alfred E. Mann is betting nearly $1 billion of his own money that he can succeed where Pfizer failed.,neutral,0.1269240528345108
2007-11-16,Betting an Estate on Inhaled Insulin,neutral,0.005776554346084595
2007-11-16,"Pfizer, the world’s biggest drug company, flopped miserably with a seemingly can’t-miss idea.",negative,-0.9161022305488586
2007-11-16,But Alfred E. Mann is so certain he can succeed that he is betting nearly $1 billion of his own money on the effort.,neutral,0.3337053954601288
2007-11-16,Betting an Estate on Inhaled Insulin,neutral,0.005776554346084595
2007-12-27,Pfizer said it would fight a Nigerian court order that could jail three employees.,negative,-0.8666332364082336
2007-12-27,WORLD BUSINESS BRIEFING: Nigeria: Pfizer Fights Jailings,negative,-0.6869679093360901
2007-12-27,AMERICAS.,neutral,0.06123775988817215
2007-12-27,World Business Briefs,neutral,0.04968610033392906
2008-01-17,European regulators raided some of the Continent’s biggest drug makers in an inquiry over whether patent disputes and lawsuits are keeping generic products off the market.,negative,-0.9092965126037598
2008-01-17,European Antitrust Regulators Raid Large Drug Makers,negative,-0.6928450465202332
2008-02-07,Dr. Robert Jarvik’s appearance in television ads for Lipitor has helped rekindle a smoldering debate.,neutral,0.1142677366733551
2008-02-07,Drug Ads Raise Questions for Heart Pioneer,neutral,-0.34095266461372375
2008-02-08,A Congressional committee wants information about people who might have served as stunt doubles for Dr. Robert Jarvik in televised ads.,negative,-0.46654263138771057
2008-02-08,Committee Investigates Ad Tactics for Lipitor,neutral,-0.04944181442260742
2008-02-21,"In the search for a new money-maker Pfizer paid $195 million for Houston-based Encysive Pharmaceuticals, a small outfit with big hopes for a breakthrough drug that, so far, the Food and Drug Administration has snubbed.",neutral,-0.06291612237691879
2008-02-21,"Looking for Next Big Hit, Pfizer Spends $195 Million on Encysive",neutral,0.050871964544057846
2008-02-25,"The ads featuring Dr. Robert Jarvik, a pioneer in artificial hearts, created false impressions, the company said.",negative,-0.805472731590271
2008-02-25,Pfizer to End Lipitor Campaign by Jarvik,neutral,-0.13303357362747192
2008-02-26,"Criticized that its ads are misleading, Pfizer said it would end a campaign using the artificial heart pioneer Robert Jarvik as a spokesman for its cholesterol drug Lipitor.",negative,-0.6916211843490601
2008-02-26,Pfizer to End Lipitor Ads by Jarvik,neutral,0.04560118913650513
2008-03-02,Improv actors know a thing or two about flexibility and creativity.,neutral,0.0573442205786705
2008-03-02,Can Executives Learn to Ignore the Script?,neutral,-0.11315324902534485
2008-05-02,"Four years after purchasing Esperion Therapeutics, a company focused on the discovery and development of compounds for cardiovascular and metabolic disease, Pfizer is selling the Ann Arbor, Mich.-based firm to an entity funded by a group of investors.",neutral,0.021661406382918358
2008-05-02,Esperion Raises $22.8 Million After Pfizer Spin-Out,positive,0.536094605922699
2008-05-03,"Pfizer has begun negotiating settlements with individual plaintiff’s firms over its Celebrex and Bextra painkillers, a New York lawyer said.",positive,0.7459267973899841
2008-05-03,Pfizer Begins Settling Painkiller Cases,neutral,0.08485069125890732
2008-06-13,"Pfizer may bid for Ranbaxy Laboratories, countering a $4.6 billion offer by Japan’s Daiichi Sankyo for the Indian generic drug maker, the Business Standard newspaper said.",positive,0.5256833434104919
2008-06-13,"Pfizer May Table Counter-Bid for India’s Ranbaxy, Report Says",neutral,0.3387985825538635
2008-06-19,The settlement of a patent dispute over the blockbuster cholesterol drug will delay the release of generic versions in the United States until 2011.,negative,-0.848432719707489
2008-06-19,Release of Generic Lipitor Is Delayed,neutral,-0.015941252931952477
2008-07-13,Social scientists have learned that there is power in tying certain behaviors to habitual cues through relentless advertising.,neutral,0.19502311944961548
2008-07-13,Warning: Habits May Be Good for You,neutral,-0.030185483396053314
2008-09-09,"Shares in German drugs and chemicals group Bayer rose on market talk of takeover interest from U.S. rival Pfizer, traders told Reuters Tuesday.",positive,0.8722874522209167
2008-09-09,Rumors of a Pfizer Deal Lift Bayer Shares,positive,0.06104043126106262
2008-10-08,"The drug maker manipulated the publication of studies to bolster use of its epilepsy drug Neurontin, according to expert witnesses in a lawsuit against the company.",neutral,-0.07718414068222046
2008-10-08,Experts Conclude Pfizer Manipulated Studies,neutral,-0.12712810933589935
2008-10-17,"Pfizer said that it had an $894 million deal to end more than 90 percent of personal injury suits brought by people claiming the drugs caused heart attacks, strokes or other harm.",positive,0.4801570177078247
2008-10-17,Pfizer to Settle Claims Over Bextra and Celebrex,neutral,0.0636257603764534
2008-10-23,Bayer shares jumped Wednesday amid market chatter that Pfizer may be interested in taking over its rival German drugs and chemicals maker.,positive,0.851097822189331
2008-10-23,Rumors of a Pfizer Bid Push Bayer Shares Up,negative,-0.40056905150413513
2008-11-28,Critics say drug firms worked to discredit a clinical trial that found that inexpensive pills for hypertension worked better than newer drugs.,negative,-0.7791038751602173
2008-11-28,The Minimal Impact of a Big Hypertension Study,neutral,0.10000909864902496
2009-01-05,"Pfizer, the world’s biggest pharmaceutical group, is open to to doing some dealmaking, The Financial Times reported.",neutral,0.4345681071281433
2009-01-05,Pfizer Said to Be on the Lookout for Takeover Targets,neutral,-0.006537087261676788
2009-01-13,The drug company plans to reduce its global research staff by 5 percent to 8 percent in an effort to refocus disappointing research efforts and cut its overhead.,negative,-0.9258143305778503
2009-01-13,Pfizer to Cut Researchers as It Hones Its Focus,negative,-0.9347268342971802
2009-01-23,"Wyeth‘s shares rose as much as 15 percent in German trading Friday, as investors reacted to a report in the Wall Street Journal that Pfizer was in in talks about potentially buying the drugmaker.",positive,0.9004478454589844
2009-01-23,"Discussions have been going on for months and a deal wasn’t imminent, the report said.",neutral,-0.2676822245121002
2009-01-23,Wyeth Shares Rise on Report of Takeover Talks,positive,0.46332401037216187
2009-01-23,"Reports that drug giant Pfizer is in talks to acquire rival Wyeth in a deal that could be worth more than $60 billion are having a treacherous effect on shares of Crucell, a Dutch biotech company.",negative,-0.8988701701164246
2009-01-23,Do Pfizer-Wyeth Talks Leave Crucell Out in the Cold?,neutral,-0.19675302505493164
2009-01-24,The purchase of Wyeth by Pfizer for more than $60 billion could be completed over the weekend.,neutral,0.06379687041044235
2009-01-24,Pfizer Said to Be Closing In on Deal for Wyeth,neutral,0.09116362780332565
2009-01-26,The deal creating a pharmaceutical giant is the first big merger backed by Wall Street in months.,positive,0.772075891494751
2009-01-26,Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth,positive,0.707148551940918
2009-01-26,"Pfizer will acquire Wyeth in a cash and stock deal valued at $68 billion, the companies said in a statement Monday morning.",neutral,0.10252033174037933
2009-01-26,Pfizer to Buy Wyeth in $68 Billion Deal,neutral,0.04559411108493805
2009-01-26,"Matthew Nugen, who became national political director for Barack Obama’s presidential campaign in early 2007, has started a new job as a strategic adviser for  Ogilvy Government Relations, a powerful lobbying firm whose clients include corporate giants such as Pfizer and big financial firms such as Blackstone.",neutral,0.05449932441115379
2009-01-26,Obama Aide Joins Ogilvy as Adviser,neutral,-0.07707890123128891
2009-01-26,The price tag isn’t the only big thing about Pfizer‘s deal to buy rival drug maker Wyeth.,neutral,0.05212992802262306
2009-01-26,Pfizer is also aiming for big synergies from the $68 billion acquisition.,positive,0.8156564831733704
2009-01-26,Pfizer Deal Calls for Ambitious Cost Cuts,neutral,0.06268014013767242
2009-01-26,"Monday’s toll included 20,000 cuts at Caterpillar, 8,000 at Sprint Nextel, 7,000 at Home Depot and 8,000 from the expected merger of Pfizer and Wyeth.",negative,-0.826147198677063
2009-01-26,"62,000 Jobs Are Cut by U.S. and Foreign Companies",negative,-0.9543477892875671
2009-01-26,Pfizer‘s $68 billion deal to buy the rival drug maker Wyeth ranks among the largest pharmaceutical deals of all time.,neutral,0.32695725560188293
2009-01-26,"The acquisition, which is being paid for in cash and Pfizer stock, also breaks a long-running drought in the merger world, which hasn’t seen such a large transaction (excluding spinoffs) since a group of banks bid nearly $96 billion for ABN Amro in April 2007.",positive,0.864255964756012
2009-01-26,Pfizer’s Prescription for Growth: Big Deals,neutral,0.17555873095989227
2009-01-26,Pfizer’s planned acquisition of Wyeth is a validation of Wyeth’s decision to reduce its reliance on small-molecule drugs.,positive,0.6200768351554871
2009-01-26,"In Wyeth, Pfizer Sees a Drug Pipeline",neutral,0.02042648196220398
2009-01-27,"Layoffs, falling stock and slim dividends leave Pfizer little to cheer about one day after the $68 billion megamerger with Wyeth.",negative,-0.9646027088165283
2009-01-27,"For Pfizer, a Big Deal and a Test",neutral,0.22098563611507416
2009-01-27,Pfizer’s move to buy Wyeth dims the hopes of struggling small biotechnology companies that wanted to sell themselves or their products to larger businesses.,negative,-0.6947251558303833
2009-01-27,Wyeth Deal May Slow Pfizer Biotech Acquisitions,negative,-0.9337224960327148
2009-01-27,Molecules.,neutral,0.05895508825778961
2009-01-27,"In Wyeth, Pfizer Sees a Drug Pipeline",neutral,0.02042648196220398
2009-01-27,"After announcing the $68 billion megamerger with Wyeth on Monday morning, Pfizer’s chief executive, Jeffrey B. Kindler, did not have much time to celebrate.",neutral,-0.33400431275367737
2009-01-27,"For Pfizer, a Big Deal and a Test",neutral,0.22098563611507416
2009-01-27,"This month Pfizer’s chief executive, Jeffrey B. Kindler, held a breakfast for venture capitalists atop a hotel in San Francisco.",neutral,0.053807422518730164
2009-01-27,Some guests took it as a sign that Pfizer was serious about buying young biotechnology companies or licensing their technology.,neutral,0.2511979341506958
2009-01-27,Wyeth Deal May Slow Pfizer Biotech Acquisitions,negative,-0.9337224960327148
2009-01-28,"An article on Tuesday about Pfizer’s $68 billion acquisition of a rival drug maker, Wyeth, misstated the price of two previous Pfizer acquisitions.",negative,-0.6559044122695923
2009-01-28,"The company paid $90 billion, not million, for Warner-Lambert in 2000, and $60 billion, not million, for Pharmacia in 2003.",neutral,0.03140448033809662
2009-01-28,Correction,neutral,0.026768818497657776
2009-01-28, Pfizer‘s mammoth bid for Wyeth is already reverberating through the pharmaceutical world.,positive,0.6622539162635803
2009-01-28,Pfizer Bid for Wyeth Bodes Well for Roche Deal,positive,0.7327565550804138
2009-01-30,"Drug giant Pfizer‘s agreement to acquire rival Wyeth would give Wyeth directors a voice on Pfizer’s board and includes hefty penalties aimed at preventing the deal from collapsing, The Associated Press reports citing a regulatory filing made Thursday.",positive,0.4829827845096588
2009-01-30,"Pfizer Deal Gives Wyeth Say on Board, Breakup Fee",neutral,0.13347052037715912
2009-01-30,"On Thursday evening, Wyeth filed the agreement for its $68 billion takeover by Pfizer.",neutral,0.13861024379730225
2009-01-30,"As the press release on Monday hinted, the Wyeth-Pfizer deal offers a new model for strategic transactions.",positive,0.6840712428092957
2009-01-30,Pfizer’s New Deal Model,neutral,0.05469684675335884
2009-02-02,Pfizer‘s $68 billion acquisition of rival pharmaceutical maker Wyeth is drawing criticism over the $22.5 billion in loans Pfizer received from major Wall Street banks to help close the deal.,negative,-0.9454479217529297
2009-02-02,Policy Group Questions Loans for Pfizer Deal,neutral,-0.0378270223736763
2009-02-10,Deals aren’t dead — just ask Pfizer or Live Nation — but they did seem to go into a coma last week.,neutral,-0.3654288649559021
2009-02-10,The Week That Deals (Almost) Dried Up,negative,-0.8787509202957153
2009-02-21,"Pfizer, the world’s biggest drug maker, is significantly reducing the value of the severance packages for top managers in a nod to public pressure to reduce executive pay.",negative,-0.9451851844787598
2009-02-21,Pfizer Reduces Executive Severance Pay,negative,-0.8660865426063538
2009-03-02,Taking a photo of opponents of drug industry influence on campus appeared to violate medical school rules.,negative,-0.8309864401817322
2009-03-02,Pfizer Worker Photographed Protesters at Harvard,negative,-0.6929425001144409
2009-03-03,More than 200 Harvard Medical School students and sympathetic faculty are intent on exposing and curtailing the industry influence in their classrooms and laboratories.,negative,-0.6711984872817993
2009-03-03,Harvard Medical School in Ethics Quandary,neutral,-0.28494906425476074
2009-03-03,The drug maker has been asked to provide details of its payments to faculty members at Harvard Medical School.,neutral,0.03531049191951752
2009-03-03,Senator Asks Pfizer About Harvard Payments,neutral,-0.0026742666959762573
2009-03-18,"Pfizer, the giant drug maker, has sold $13.5 billion worth of bonds to replace short-term loans covering about one-third of the cost of its planned acquisition of its rival Wyeth, The Associated Press said.",positive,0.5786244869232178
2009-03-18,Pfizer Sells $13.5 Billion in Bonds for Wyeth Deal,neutral,0.06090455874800682
2009-04-16,"The pharmaceutical giants GlaxoSmithKline and Pfizer said they would form a specialty company to research, develop and market treatments for H.I.V.",neutral,0.343488484621048
2009-04-16,Glaxo and Pfizer Join Forces to Develop and Market H.I.V.,neutral,0.4778696894645691
2009-04-16,Drugs,neutral,0.0437769740819931
2009-04-17,GlaxoSmithKline and Pfizer plan to spin out and combine their H.I.V.,neutral,0.039847228676080704
2009-04-17,"research units, choosing an alternative to the big mergers that have been transforming the industry.",neutral,0.08009941130876541
2009-04-17,A Different Kind of Drug Deal,neutral,0.04138844832777977
2009-04-28,"As Pfizer sails toward its merger with Wyeth, it is hitting headwinds from patent expirations and weakening in sales in some key products, including Lipitor.",negative,-0.9684783816337585
2009-04-28,Pfizer Profit Dips on Ease in Demand for Lipitor,negative,-0.9449487328529358
2009-05-04,"The proposed tax overhaul, aimed at benefits enjoyed by those harboring cash in offshore accounts, could help raise $210 billion, the administration estimates.",positive,0.8310427665710449
2009-05-04,Obama Calls for Curbs on Offshore Tax Havens,neutral,-0.3028513491153717
2009-06-15,"Pfizer is looking to conclude deals in emerging markets over “few months” to raise its share in a market estimated at $80 billion, a Pfizer executive told Reuters.",positive,0.9120061993598938
2009-06-15,Pfizer Looks to Raise Presence in Emerging Markets,positive,0.901371955871582
2009-06-18,Wyeth has scheduled a meeting for its shareholders to vote on whether to approve its pending acquisition by Pfizer.,neutral,0.05605558305978775
2009-06-18,Wyeth Sets Meeting for Shareholders’ Merger Vote,neutral,0.013598311692476273
2009-09-02,"Companies are pouring billions into developing cancer drugs, lured by the high prices such drugs can command.",neutral,0.346495121717453
2009-09-02,"For Profit, Industry Seeks Cancer Drugs",neutral,-0.03191830962896347
2009-09-02,The government charged that executives throughout the company planned schemes to illegally market Bextra and other drugs.,negative,-0.8506979942321777
2009-09-02,Pfizer Pays $2.3 Billion to Settle Marketing Case,neutral,0.025337455794215202
2009-09-03,"Pfizer agreed to pay $2.3 billion to settle civil and criminal allegations that it had illegally marketed its painkiller Bextra, which has been withdrawn.",neutral,0.009537935256958008
2009-09-03,Pfizer Pays $2.3 Billion to Settle Marketing Case,neutral,0.025337455794215202
2009-09-30,The drug maker still needs approval from the United States and Candada for its $68 billion buyout of a rival.,neutral,0.1858707070350647
2009-09-30,Pfizer Gets Approval From China and Australia for Wyeth Deal,positive,0.5751570463180542
2009-10-15,"Pfizer’s $68 billion purchase of Wyeth will close Thursday after antitrust regulators in the U.S. and Canada cleared the deal, which will make Pfizer the world’s largest drugmaker by revenue.",positive,0.43514448404312134
2009-10-15,U.S. and Canada Approve Pfizer-Wyeth Deal,positive,0.6559049487113953
2009-10-28,Pfizer just announced it is giving two senior vice presidents bonuses of $1 million and $1.2 million for their deft handling of the $68 billion Wyeth buyout in the midst of the global financial crisis.,positive,0.4819124937057495
2009-10-28,"For Closing Wyeth Deal, Pfizer Doles Out Rewards",negative,-0.5016086101531982
2009-11-05,"At their worst, bonuses for acquisitions encourage empire-building and widen the gap between the interests of management and those of shareholders.",neutral,0.39373791217803955
2009-11-05,"Offer Incentives, but Carefully",neutral,0.07732368260622025
2009-11-05,"If not carefully handled, bonuses awarded to chief executives for selling their company can widen the gap between the interests of management and those of shareholders, Breakingviews argues.",neutral,0.25692468881607056
2009-11-05,Should C.E.O.s Be Rewarded for Dealmaking?,positive,0.8189799785614014
2009-11-24,The drug maker has been ordered to pay punitive damages to two women whose breast cancer was diagnosed after they used hormone drugs.,negative,-0.917320966720581
2009-11-24,Another Loss for Pfizer in Drug Suits,negative,-0.8840163946151733
2009-12-01,"Pfizer said that it had licensed the worldwide rights to a treatment for Gaucher disease, a genetic disorder, putting Pfizer into competition with Genzyme.",positive,0.7571592926979065
2009-12-01,Pfizer Deal Signals a Move Into Treating Rare Diseases,positive,0.5883904695510864
2009-12-02,"Pfizer said Tuesday that it had licensed the worldwide rights to a treatment for Gaucher disease, a rare genetic disorder, from Protalix Biotherapeutics, an Israeli biotechnology company.",positive,0.6822906732559204
2009-12-02,Pfizer Deal Signals Move Into Rare Diseases,neutral,0.05696941912174225
2009-12-12,"Two pharmaceutical companies have developed drugs to fight premature ejaculation, and hope they will become blockbusters like drugs for erectile dysfunction.",positive,0.5581178665161133
2009-12-12,"Sure, It’s Treatable.",neutral,-0.06276749819517136
2009-12-12,But Is It a Disorder?,neutral,-0.4108753502368927
2009-12-12,Lawsuits and internal documents show how Pfizer and its predecessors promoted the idea of taking hormone drugs.,neutral,-0.06345687806606293
2009-12-12,"Menopause, as Brought to You by Big Pharma",neutral,0.011764428578317165
2009-12-21,"Pfizer will have the rights to develop Athersys’s cells to treat inflammatory bowel disease, which is in early human testing.",neutral,0.12105803191661835
2009-12-21,Pfizer Acquires a Stem-Cell Therapy,neutral,0.23038749396800995
2009-12-21,"Pfizer said it was buying the rights to a somewhat controversial cell therapy from Athersys, a biotechnology company — a sign of big pharmaceutical companies’ growing interest in stem cells.",neutral,0.44523096084594727
2009-12-21,Pfizer Acquires a Stem-Cell Therapy,neutral,0.23038749396800995
2009-12-28,"In part one of his 2009 year in review, the Deal Professor examines the general trends of what he predicts will be a flatter deal-making landscape for some time to come.",neutral,0.052501779049634933
2009-12-28,"The Deal Professor’s 2009 in Review, Part I: No Exit",neutral,0.011261619627475739
2010-01-09,Why corporate apologies could mean a lot — for patients and for employees.,negative,-0.4829955995082855
2010-01-09,Is ‘Sorry’ the Hardest Word in Health Care?,negative,-0.5126596689224243
2010-01-11,"With a $3 million grant, Stanford University is planning a continuing education program for doctors that is free of drug industry influence.",neutral,0.29997047781944275
2010-01-11,"Using a Pfizer Grant, Courses Aim to Avoid Bias",neutral,0.028060896322131157
2010-01-15,Stocks advanced for a second day as technology shares climbed before Intel reported earnings.,positive,0.6801894903182983
2010-01-15,"In addition, business inventories increased more than forecast, overshadowing an unexpected drop in retail sales.",positive,0.6409142017364502
2010-01-15,Technology Helps Shares Higher as Retailers Slip,positive,0.6458633542060852
2010-02-01,The year started off exceptionally slow for mergers and acquisitions in the United States.,negative,-0.740170419216156
2010-02-01,"There was only $34.2 billion worth of announced deals in January, according to Standard & Poor’s Capital IQ, making it the slowest first month of the year since 2003.",negative,-0.951840877532959
2010-02-01,Big Chill Hit the Deal Market in January,negative,-0.6602950096130371
2010-02-04,"The company’s quarterly profit more than doubled but the results were hurt by costs associated with the purchase of Wyeth, a rival drug maker.",negative,-0.9619690179824829
2010-02-04,"Pfizer Misses Estimates, and Shares Slide",negative,-0.9343366622924805
2010-02-04,"Investors were cautious on Wednesday as concerns over high unemployment and the ability of businesses to bring in revenue resurfaced, tempering some of the zeal that had marked Wall Street earlier this week.",negative,-0.8458672761917114
2010-02-04,"Concerned Over Jobs and Revenue, Wall St. Wanders",negative,-0.8494168519973755
2010-02-05,"Without the regulatory certainty stemming from the health care bill, drug companies face unpleasant surprises like a heavier tax on foreign income.",negative,-0.7963857650756836
2010-02-05,Stalled Health Care Bill Leaves Drug Makers in Regulatory Limbo,negative,-0.8992644548416138
2010-02-16,"Drug makers are pursuing a consumer base in markets like Asia and Latin America, where many pay out of pocket for medicines but often cannot afford expensive brand-name drugs.",neutral,0.13337045907974243
2010-02-16,Drug Firms Apply Brand to Generics,neutral,-0.001171991229057312
2010-02-17,"AstraZeneca waded into the competitive rheumatoid arthritis market on Tuesday by buying rights to Rigel Pharmaceuticals’ next-generation drug R788 for up to $1.245 billion, Reuters reported.",positive,0.8340912461280823
2010-02-17,Astra Pays Up to $1.2 Billion for Arthritis Drug,neutral,0.07255036383867264
2010-02-17,"Merck posted quarterly revenue above analysts’ estimates on Tuesday, helped by strong sales of its diabetes and allergy drugs, Reuters reported.",positive,0.913547694683075
2010-02-17,"In Wake of Merger, Merck Beats Forecasts",negative,-0.7288373112678528
2010-02-18,"Actavis has severed ties with Sweden’s EQT in a bid for German drug maker Ratiopharm, Reuters reported.",negative,-0.8860943913459778
2010-02-18,Actavis Relies on Deutsche for Ratiopharm Bid,neutral,0.020262423902750015
2010-03-01,"Mr. Gilgore, an opera lover, had roles in the advancement of drugs like Ambien and Celebrex.",neutral,0.028827590867877007
2010-03-01,"Sheldon Gilgore, Physician Who Led Drug Giants Pfizer and Searle, Dies at 77",neutral,-0.3432585597038269
2010-03-02,"Some big hedge funds are feeling the love for Pfizer, now that it has Wyeth’s pipeline, Reuters reports.",neutral,0.43664050102233887
2010-03-02,Hedge Funds Heart Pfizer,neutral,0.0021584555506706238
2010-03-02,"Pfizer is reportedly gearing up this week to bid 3 million euro ($4.08 billion) for Ratiopharm, a generic drug maker based in Germany.",positive,0.5796587467193604
2010-03-02,Pfizer Said to Set Sights on German Drug Maker,neutral,0.053946156054735184
2010-03-03,"Bristol-Myers Squibb, the drug maker, said Tuesday that its chief executive would retire in May and be succeeded by the chief operating officer.",neutral,-0.03695283085107803
2010-03-03,Management Shuffle at Bristol-Myers,neutral,0.019710302352905273
2010-03-03,"The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer.",negative,-0.9330611824989319
2010-03-03,Hopes for Alzheimer’s Drug Are Dashed,neutral,-0.15635663270950317
2010-03-03,"The Deal Professor examines how the structure of deals has changed and tightened in the wake of the financial crisis, when a number of transactions collapsed.",neutral,0.016279757022857666
2010-03-03,"Post-Crisis, the Evolving Structure of Deals",neutral,0.016400299966335297
2010-03-08,Pfizer and two competitors with their eyes on global growth pursue a big maker of generics.,neutral,0.084431491792202
2010-03-08,Bidding War Pits Pfizer And Teva,neutral,-0.015211571007966995
2010-03-09,"The Ratiopharm auction is riveting drug makers and analysts because it pits the world’s biggest maker of brand-name drugs, the U.S. company Pfizer, against the global leader in generics, Israel’s Teva Pharmaceutical Industries.",positive,0.10958197712898254
2010-03-09,Bidding War Pits Pfizer Against Teva,negative,-0.6813974976539612
2010-03-09,"Lacking a clear consensus about the strength of the recovery, Wall Street fell into a seesaw pattern on Monday.",negative,-0.9478753209114075
2010-03-09,Hesitation on Wall Street Leaves Shares Flat,negative,-0.6089398264884949
2010-03-18,"Teva Pharmaceutical Industries has won the bidding contest for German generic drug maker Ratiopharm, beating out Pfizer and Actavis, three people close to the matter told Reuters.",positive,0.8959238529205322
2010-03-18,Teva to Acquire Ratiopharm for $5 Billion,neutral,0.010490832850337029
2010-03-23,"The agreement, with Pfizer and GlaxoSmithKline, could save as many as 900,000 lives over the next five years.",neutral,0.32526469230651855
2010-03-23,Deal Provides Vaccines to Poor Nations at Lower Cost,positive,0.4856414198875427
2010-03-27,"About 80 percent of prescriptions for nitroglycerin are filled with unapproved, unvetted tablets, the agency said.",neutral,-0.04059688374400139
2010-03-27,F.D.A.,neutral,0.04497655853629112
2010-03-27,Says Millions Got Unapproved Heart Pills,negative,-0.38612860441207886
2010-03-31,"The drug company said it paid about $20 million to 4,500 doctors and other professionals for consulting and speaking on its behalf.",neutral,0.048354826867580414
2010-03-31,Pfizer Gives Details on Payments to Doctors,neutral,0.012610817328095436
2010-04-01,Producing new drugs and adjusting to the changing health care system are two of the tests facing the drug giant.,neutral,0.07589433342218399
2010-04-01,Pfizer Chief Says Growth Is Imminent,positive,0.795406699180603
2010-04-03,A jury ruled that Pfizer violated laws protecting free speech and whistle-blowers by retaliating against a worker who said she was sickened by a genetically engineered virus at the company.,negative,-0.9356639981269836
2010-04-03,A Pfizer Whistle-Blower Is Awarded $1.4 Million,neutral,0.3294154703617096
2010-04-09,Another private equity firm has snapped up a high-profile former chief executive.,negative,-0.4776541590690613
2010-04-09,"The Carlyle Group announced that it had hired Wyeth’s former chief, Robert Essner, as a senior adviser to its Global Healthcare group, Reuters reported.",neutral,0.328359991312027
2010-04-09,Carlyle Hires Former Wyeth Chief,neutral,-0.26739710569381714
2010-04-12,Disclosure advocates say it is not easy enough to use the companies’ Web sites to find out which doctors are getting the most money.,negative,-0.5380550622940063
2010-04-12,Data on Fees to Doctors Is Called Hard to Parse,negative,-0.8473471403121948
2010-05-21,"Abbott Laboratories will pay $3.72 billion to acquire India’s Piramal Healthcare’s pharmaceutical solutions business, as global drugmakers look to boost their presence in emerging markets, Reuters reported.",positive,0.8877884745597839
2010-05-21,Abbott in $3.7 Billion Deal for Piramal Unit in India,neutral,0.27481305599212646
2010-05-27,Biotechnology labs are filled with imponderable hazards yet are subjected to fewer regulations than most factories.,neutral,0.021999381482601166
2010-05-27,Safety Rules Can’t Keep Up With Biotech Industry,negative,-0.7271826863288879
2010-07-06,"Last week, Standard & Poor’s lent its insight into European companies ripe for being acquired.",positive,0.7375795841217041
2010-07-06,"This week, the firm’s analysts are taking a look at who might do the buying.",neutral,0.0032285917550325394
2010-07-06,A Peek at U.S. Companies Set for European Deals,neutral,0.05350346863269806
2010-07-21,Stocks closed a lightly traded session higher Tuesday despite disappointing earnings from Goldman Sachs and Johnson & Johnson.,positive,0.5139328241348267
2010-07-21,Wall Street Ends the Day Higher,neutral,-0.1333184540271759
2010-07-22,"A little more than a year after acquiring Genentech, Roche said Thursday that its profits for the first half of this year had risen by 37 percent from the same period a year before as exceptional costs associated with the merger had fallen.",positive,0.8715684413909912
2010-07-22,Roche Profit Up on Genentech Synergies,positive,0.8330488204956055
2010-09-04,"Pfizer is pulling out of an agreement with Celldex Therapeutics to finance the development of an experimental brain tumor vaccine, Celldex said Friday.",negative,-0.9320117235183716
2010-09-04,Celldex Loses a Partner in Brain Tumor Treatment,negative,-0.8945131897926331
2010-09-22,The drug maker and its Wyeth unit are accused by two whistle-blowers of illegal off-label marketing of a drug used to prevent rejection of kidney transplants.,negative,-0.8992118835449219
2010-09-22,U.S.,neutral,-0.05536564439535141
2010-09-22,Joins Pfizer Suit Over Drug’s Marketing,negative,-0.7646837830543518
2010-09-29,"Markets in the United States on Tuesday erased most of their losses from Monday, as Walgreen led a rally in consumer staples and health companies Investors also speculated that the Federal Reserve would buy more debt to safeguard the economy.",positive,0.06048226356506348
2010-09-29,Healthcare Helps Wall Street Rebound Quickly,positive,0.4733874499797821
2010-10-11,The Supreme Court’s review of the no-fault system for vaccines could have an effect on hundreds of lawsuits over childhood vaccines and autism.,negative,-0.6231009364128113
2010-10-11,Supreme Court to Consider Vaccine Case,neutral,-0.04976535588502884
2010-10-12,"Pfizer agreed to buy the maker of pain medication for $3.6 billion in cash, in the giant drug maker’s first major deal since its blockbuster purchase of Wyeth last year.",positive,0.7820146083831787
2010-10-12,Pfizer to Buy King Pharmaceuticals for $3.6 Billion,neutral,0.027645161375403404
2010-10-15,"The potential bids follow an announcement by Pfizer last week that it was considering selling the drug capsule business, Capsugel.",neutral,0.06761828064918518
2010-10-15,Blackstone and Bain Plan Bids for Pfizer Capsule Unit,neutral,0.030293183401226997
2010-10-18,The Deal Professor examines 11 deals in the first half of October for signs of how the mergers and acquisition market will play out next year.,neutral,0.027727477252483368
2010-10-18,What Recent Deals May Say About M.&A.’s Future,neutral,0.03139235079288483
2010-11-25,"Ireland plans to keep low rates that have attracted Microsoft, Intel and Pfizer but that other countries say distort competition.",neutral,0.15577927231788635
2010-11-25,"In Ireland, Low Corporate Taxes Go Untouched",neutral,0.04745429754257202
2010-12-04,"In a preliminary settlement agreement, Pfizer tries to address lawsuits accusing its board and top officials of failing to stop illegal marketing of its drugs.",negative,-0.8402454853057861
2010-12-04,Pfizer Plans $75 Million Fund to Address Shareholder Suits,neutral,0.03776392340660095
2010-12-06,"Jeffrey B. Kindler’s retirement comes almost two years after he led Pfizer’s bid for Wyeth, the first major deal after the financial crisis.",neutral,0.03983350098133087
2010-12-06,Pfizer Loses Man Behind Wyeth Deal,negative,-0.7411851286888123
2010-12-06,"Jeffrey Kindler will be succeeded as chief executive by Ian Read, and the board will vote on a new chairman within two weeks.",neutral,-0.0029217563569545746
2010-12-06,Pfizer’s Chairman and Chief Retires Unexpectedly,neutral,-0.11186148226261139
2010-12-06,"David Einhorn, the president of Greenlight Capital, tells CNBC he likes Sprint Nextel, Apple and Pfizer.",neutral,0.05295329540967941
2010-12-06,Where Einhorn Is Investing Now,neutral,0.05173886567354202
2010-12-07,"Shareholders lost about 20 percent of their investment during Pfizer’s chief executive, Jeffrey B. Kindler’s four-and-a-half-year tenure.",negative,-0.9517916440963745
2010-12-07,Pfizer’s Falling Share Price Couldn’t Be Cured,negative,-0.8292093873023987
2010-12-08,"Johnson & Johnson made a formal offer on Wednesday for Crucell, a Dutch biotechnology company.",neutral,0.26138946413993835
2010-12-08,J.&J.,neutral,0.043579064309597015
2010-12-08,Bids $2.3 Billion for Crucell,neutral,0.10531012713909149
2010-12-09,"In total, Jeffrey B. Kindler, who resigned unexpectedly as chief executive and chairman, will receive $9.5 million in cash in addition to stock and retirement benefits.",neutral,0.07935816049575806
2010-12-09,Pfizer to Pay Its Ex-Chief $4.5 Million in Severance,neutral,-0.1188938319683075
2010-12-10,"Tor Myhren’s promotion is the first time Grey New York will be led by its chief creative officer, a position he will keep.",neutral,0.13067197799682617
2010-12-10,Grey New York to Be Led by Its Chief Creative Officer,neutral,0.02823793515563011
2010-12-11,A secret cable indicated that information about the Nigerian attorney general was spread through the media to publicly pressure him to drop lawsuits against Pfizer.,negative,-0.6720972061157227
2010-12-11,Secret Cable Discusses Pfizer’s Actions in Nigeria Case,neutral,-0.0028623417019844055
2011-01-03,"After a rise in the cigarette tax, demand for a Pfizer antismoking drug outstripped the supply.",negative,-0.5126404762268066
2011-01-03,"In Japan, Pfizer Is Short of Drug to Help Smokers",negative,-0.6784770488739014
2011-01-18,"The deal, worth up to $632 million, is part of Pfizer’s effort to keep up with rivals that are increasingly relying on biotechnology for products and profits.",positive,0.7924842238426208
2011-01-18,Pfizer in Deal With Theraclone for Antibody Drug Research,neutral,-0.035589322447776794
2011-01-29,A judge in Boston upheld a jury decision that Pfizer illegally promoted Neurontin for unapproved uses.,negative,-0.8521962761878967
2011-01-29,Pfizer said it would appeal.,neutral,0.08100319653749466
2011-01-29,Pfizer Told to Pay $142.1 Million Over Marketing of Epilepsy Drug,neutral,-0.13747210800647736
2011-02-01,"Valeant Pharmaceuticals says it will acquire PharmaSwiss, a maker of generic drugs, for 350 million euros.",neutral,0.06997083872556686
2011-02-01,Valeant to Buy PharmaSwiss for $481 Million,neutral,0.013396280817687511
2011-02-02,"Pfizer said it planned to close a facility in Britain, reduce research spending and invest in money-making drugs.",neutral,0.12143310159444809
2011-02-02,New Chief Revises Goals and Spending for Pfizer,neutral,0.06117895990610123
2011-02-22,The Supreme Court ruled against the parents of a child who sued the drug maker Wyeth because of the health problems they say their daughter suffered from a vaccine.,negative,-0.863322377204895
2011-02-22,Justices Reject Suit Faulting a Vaccine,negative,-0.7119951844215393
2011-03-07,"The drug industry will lose control over more than 10 medicines with sales of nearly $50 billion this year, a reversal that highlights the problems drug companies now face.",negative,-0.9512220025062561
2011-03-07,Drug Firms Face Billions in Losses in ’11 as Patents End,negative,-0.9351938962936401
2011-04-04,The $2.375 billion deal may be a harbinger amid speculation that Pfizer will sell or spin off its nonpharmaceutical businesses.,negative,-0.727763831615448
2011-04-04,Pfizer Sells Capsule Unit to K.K.R.,neutral,0.009116037748754025
2011-04-13,The multibillion-dollar market is being driven by novel applications to compete with coming generics.,positive,0.804340124130249
2011-04-13,"As Generics Near, Makers Tweak Erectile Drugs",neutral,0.06507565081119537
2011-06-09,Concerns about 3-Nitro have gotten the attention of the Food and Drug Administration.,neutral,-0.04396335408091545
2011-06-09,Pfizer Suspends Sales of Chicken Drug With Arsenic,negative,-0.822549045085907
2011-06-23,"The proposed medication, from Bristol-Myers Squibb and Pfizer, prevents more strokes with less bleeding risk than existing treatment.",neutral,0.39944779872894287
2011-06-23,It needs F.D.A.,neutral,-0.174398735165596
2011-06-23,approval.,positive,0.477968692779541
2011-06-23,Anticlotting Drug Shows Promise to Displace a Longtime Standard,positive,0.6425486207008362
2011-07-04,Chantix was linked to an increased risk of a heart attack or other serious cardiovascular event for smokers without a history of heart disease.,negative,-0.4235941171646118
2011-07-04,Study Links Smoking Drug to Cardiovascular Problems,neutral,-0.2326565682888031
2011-07-07,The drug maker steps up a streamlining effort to focus on its core business.,positive,0.7161502242088318
2011-07-07,Pfizer Puts Nutrition and Animal Health Units on the Block,neutral,0.010599867440760136
2011-08-02,Sales of the company’s Lyrica pain pill and its Enbrel arthritis medicine topped analysts’ predictions.,positive,0.8811731934547424
2011-08-02,Sales of Pain Drugs Help Pfizer’s Profit Beat Forecasts,positive,0.8083574771881104
2011-08-04,Pfizer hopes to have an over-the-counter version of the world’s best-selling drug after it loses patent protection.,neutral,-0.12980729341506958
2011-08-04,Pfizer Is Said to Pursue Nonprescription Lipitor,neutral,0.015263537876307964
2011-11-12,Pfizer is offering to give discounts on Lipitor to pharmacists who keep filling prescriptions with the name-brand drug once generic competition begins.,positive,0.64289391040802
2011-11-12,Plan Would Delay Sales of Generic for Lipitor,negative,-0.9051036238670349
2011-11-22,"As the nation seeks ways to create jobs, critics say many big companies are squandering resources on share repurchases at the expense of investing in future growth.",negative,-0.8948118090629578
2011-11-22,"As Layoffs Rise, Stock Buybacks Consume Cash",negative,-0.9122257232666016
2011-11-30,Pfizer’s aggressive strategy may offer lessons for drug makers facing similar losses of patent protection for other blockbuster drugs over the next few years.,positive,0.8833273649215698
2011-11-30,"Facing Generic Lipitor Rivals, Pfizer Battles to Protect Its Cash Cow",negative,-0.8793945908546448
2011-12-01,"Three senators asked Pfizer to detail their agreements to block prescriptions of generic versions of Lipitor, saying they were against the idea of drug makers manipulating the marketplace.",negative,-0.7914652824401855
2011-12-01,Senators Question Deals to Block Generic Lipitor,negative,-0.8588549494743347
2011-12-10,"Amy Schulman of Pfizer says that when conveying your management style to employees, it’s always best to give real-life examples.",neutral,0.0038429517298936844
2011-12-10,"A Blueprint for Leadership: Show, Don’t Tell",neutral,-0.07071685791015625
2012-02-12,"Mr. Aaron was one of the most notable deal-makers of his generation, having counseled a long list of blue-chip clients that included General Motors, Time Warner and Pfizer.",neutral,0.07807905972003937
2012-02-12,"Roger S. Aaron, Top Deal Lawyer, Dies at 69",neutral,-0.2613641321659088
2012-03-06,"The proposed new drug would combine Merck’s drug Zetia, which lowers “bad” cholesterol, with the generic version of Lipitor, the statin made by Pfizer.",neutral,0.2850050926208496
2012-03-06,"In Rejection, F.D.A.",neutral,-0.2910013198852539
2012-03-06,Wants More Data From Merck,neutral,0.03371535241603851
2012-03-28,The new owners of Pfizer’s former factory in Williamsburg are bringing manufacturing jobs back to the borough in what was the pharmaceutical giant’s original home.,positive,0.49382320046424866
2012-03-28,Food Start-Ups Find a Home in Brooklyn,neutral,0.07823846489191055
2012-04-02,"Through their holding company, Joh.",neutral,0.008284959942102432
2012-04-02,"A. Benckiser, the Reimanns own some of the world’s most recognizable consumer brands, including Coty, Bally, Derek Lam, and the Reckitt Benckiser Group, a giant maker of household cleaning supplies.",neutral,0.07372701168060303
2012-04-02,The Billionaire Family Backing the Avon Bid,neutral,-0.012820258736610413
2012-04-12,"So-called specialty drugs for diseases like rheumatoid arthritis have a narrow use and high costs, leaving the most vulnerable patients with huge bills.",negative,-0.8317885398864746
2012-04-12,States Seek Curb on Patient Bills for Costly Drugs,negative,-0.7052120566368103
2012-04-18,"Pfizer, which has been selling off units to concentrate on development of medicines, may be ready to sell the nutrition unit to Nestlé.",neutral,0.005695518106222153
2012-04-18,Pfizer Nears Sale of Infant Nutrition Unit,neutral,-0.059577424079179764
2012-04-18,"Pfizer, which has been selling off units to concentrate on development of medicines, may be ready to sell the nutrition unit to Nestlé.",neutral,0.005695518106222153
2012-04-18,Pfizer Close to Selling Another Unit,neutral,-0.20354034006595612
2012-04-23,"Amid a weak merger market, drug makers are striking a flurry of deals, with Pfizer agreeing to sell its infant nutrition unit to Nestlé for $11.9 billion on Monday.",positive,0.6557347774505615
2012-04-23,A Hot Time for Health Care Deals,neutral,0.07518430054187775
2012-04-23,"Adding to a flurry of health care deals announced on Monday, Thomson Reuters has sold its health care unit to an affiliate of Veritas Capital for $1.25 billion in cash.",neutral,0.05838417261838913
2012-04-23,Thomson Reuters Sells Health Care Business for $1.25 Billion,neutral,0.008492198772728443
2012-04-23,"By agreeing to acquire Pfizer’s infant nutrition business for $11.9 billion, the Swiss food giant Nestlé is paying a high premium to gain access to the baby food markets in emerging countries.",positive,0.8784569501876831
2012-04-23,Nestle Pays a High Price for Pfizer Unit,neutral,0.06230976805090904
2012-05-02,"With its best-selling drugs losing patent protection, Pfizer is shedding money-making but noncore businesses to focus on pharmaceutical sciences.",negative,-0.6715612411499023
2012-05-02,Pfizer Races to Reinvent Itself,neutral,0.2005787044763565
2012-05-08,"As an advisory panel prepared to consider whether to recommend federal approval of Pfizer’s rheumatoid arthritis pill, F.D.A.",neutral,0.22392819821834564
2012-05-08,documents raise safety questions.,neutral,-0.23471757769584656
2012-05-08,F.D.A.,neutral,0.04497655853629112
2012-05-08,Staff Raises Concerns About Arthritis Drug,negative,-0.7272430062294006
2012-05-09,"A federal advisory panel recommended approval of a rheumatoid arthritis pill known as tofacitinib, but several members expressed concern about its safety.",negative,-0.7449619770050049
2012-05-09,Arthritis Pill From Pfizer Wins Support of U.S. Panel,positive,0.7727378010749817
2012-06-01,"Cavan M. Redmond, a senior executive at Pfizer, will become the chief executive of WebMD, which is under pressure to bolster its share price.",neutral,0.1847139298915863
2012-06-01,Pfizer Executive to Take the Helm of WebMD,neutral,7.330998778343201e-05
2012-06-07,Shares in Pfizer were up slightly on Thursday after the drug maker announced that it planned to take its animal health unit public rather than sell it.,positive,0.8961232900619507
2012-06-07,Pfizer Confirms Spinoff of Animal Health Unit,neutral,0.060578733682632446
2012-06-25,Documents in a fraud case against Pfizer suggest that research officials were less than forthcoming about the safety of the arthritis drug Celebrex during an early trial study.,negative,-0.8981291055679321
2012-06-25,"In Documents on Pain Drug, Signs of Doubt and Deception",neutral,-0.3249216079711914
2012-06-26,"The drug’s makers said the agency had asked for more information on managing and verifying data from a large study that compared the drug, Eliquis, with warfarin.",neutral,0.346301406621933
2012-06-26,F.D.A.,neutral,0.04497655853629112
2012-06-26,Unexpectedly Delays Move on Anticlotting Drug,negative,-0.921362042427063
2012-07-24,"Pfizer, one of the three companies behind the drug, said it did not improve either cognition or daily functioning compared to a placebo.",negative,-0.8337401747703552
2012-07-24,Alzheimer’s Drug Fails Its First Big Clinical Trial,negative,-0.9001184701919556
2012-08-06,"The companies developing the treatment, called bapineuzumab, said it did not improve cognition or daily functioning compared with a placebo.",negative,-0.7698800563812256
2012-08-06,Trials for Alzheimer’s Drug Halted After Poor Results,negative,-0.944524347782135
2012-08-07,The pharmaceutical company and a subsidiary will pay a total of $60 million to resolve accusations that it paid doctors in several countries to prescribe its drugs.,negative,-0.4652863144874573
2012-08-07,Pfizer Settles U.S. Charges of Bribing Doctors Abroad,negative,-0.3280426263809204
2012-08-08,"Jeffrey B. Kindler, who retired as Pfizer’s chairman and chief executive at the end of 2011, has joined Lux Capital as a venture partner, the firm announced on Wednesday.",neutral,0.06540580093860626
2012-08-08,"Kindler, Former Pfizer Chief, Joins Lux Capital",neutral,-0.011005908250808716
2012-08-13,"The company that will be spun off, to be called Zoetis, has about $4.2 billion in annual revenue and could be valued at $15 billion or more.",neutral,0.005448510870337486
2012-08-13,Pfizer Animal Health Unit Files for I.P.O.,neutral,-0.07715046405792236
2012-09-07,"Mylan, the maker of the epinephrine injector EpiPen, is expanding its marketing efforts in the face of new, competing devices and the surging rates of allergies in children.",positive,0.8676183223724365
2012-09-07,Tiny Lifesaver for a Growing Worry,neutral,0.07407715171575546
2012-11-06,"In trials, use of the experimental drugs reduced so-called bad cholesterol by about 40 to 70 percent in a matter of weeks, equivalent to the reduction achieved by the most effective statins like Lipitor.",positive,0.39038190245628357
2012-11-06,New Drugs for Lipids Set Off Race,neutral,0.31521162390708923
2012-12-29,Eliquis is the third anticlotting medicine to be approved recently and it is expected the backers will aggressively market their products.,positive,0.7251624464988708
2012-12-29,F.D.A.,neutral,0.04497655853629112
2012-12-29,Clears Anticlotting Drug by Bristol and Pfizer,neutral,0.03600398451089859
2013-01-12,An Alabama court ruled that a patient could sue a brand-name company for failing to warn about a drug’s risks even though he took a generic version.,negative,-0.8952811360359192
2013-01-12,Man Taking Generic Drug Can Sue Branded Maker,negative,-0.5382056832313538
2013-01-31,"The Pfizer division, known as Zoetis, exceeded expectations by pricing its stock at $26 a share in an initial public offering that values the company at about $13 billion.",positive,0.48804545402526855
2013-01-31,Pfizer Spins Off Animal Health Unit in $2.2 Billion I.P.O.,neutral,-0.37440812587738037
2013-02-01,Shares of the Pfizer animal health spinoff — the biggest initial public offering in the United States since Facebook’s last spring — make an impressive market entrance.,positive,0.8973869681358337
2013-02-01,Shares of Zoetis Surge on Debut,positive,0.6692769527435303
2013-03-19,Congress wants a second look at how private firms profit from public research after Pfizer and the National Institutes of Health developed a potentially lucrative new drug.,neutral,0.07096423953771591
2013-03-19,Seeking Profit for Taxpayers in Potential of New Drug,neutral,0.19106203317642212
2013-05-04,"The drug pairs Merck’s Zetia, which lowers low-density lipoprotein, with the generic version of Lipitor, the best-selling statin made by Pfizer that lost its patent protection in 2011.",neutral,0.13000978529453278
2013-05-04,Drug to Cut Cholesterol Is Approved by the F.D.A.,neutral,0.4262012839317322
2013-05-07,"The drug maker is now selling its billion-dollar erectile dysfunction drug, among the world’s most counterfeited, directly to men with a prescription.",neutral,0.07056522369384766
2013-05-07,"Facing Black Market, Pfizer Is Looking Online to Sell Viagra",neutral,0.06694653630256653
2013-07-31,The Justice Department announced that the drug maker would settle criminal and civil charges over illegal marketing of the kidney-transplant drug Rapamune.,negative,-0.7294240593910217
2013-07-31,Pfizer Settles a Drug Marketing Case for $491 Million,negative,-0.339813232421875
2013-08-27,"Tax policy experts are suspicious of tax holidays, and most experts question the effectiveness of attaching restrictions to such legislation.",negative,-0.662703275680542
2013-08-27,Many companies find a way around them.,neutral,0.04025629162788391
2013-08-27,"A Holiday From Taxes, and Often From the Strings Attached",neutral,-0.08158418536186218
2013-10-12,"The executives, ranging from the president of a beauty products company to the general counsel at Pfizer, shared their stories about headwinds they have navigated over the years and advice to women wanting to succeed at work.",neutral,0.12964586913585663
2013-10-12,Four Executives on Succeeding in Business as a Woman,neutral,0.13134273886680603
2013-11-20,"A proposal by Senator Max Baucus to revise international tax rules would help financial services firms that tend to have high effective tax rates, the author writes.",positive,0.7059943675994873
2013-11-20,Wall Street Could Benefit From Tax Proposal,positive,0.6131913065910339
2013-12-31,"Questions about Zilmax, a feed additive made by Merck, show the market dangers of an increasingly complicated global food chain, Kevin Allison of Reuters Breakingviews writes.",negative,-0.7264078855514526
2013-12-31,The Risks of Investing in Animal Medicine,neutral,0.011288225650787354
2014-03-10,"Minerals Technologies agreed to pay about $1.7 billion, beating out Imerys of France, after a spirited back-and-forth for Amcol, a producer of specialty minerals and materials based in Illinois.",positive,0.8172205686569214
2014-03-10,Minerals Technologies Wins Bidding War for Amcol International,positive,0.6357507705688477
2014-04-06,"Palbociclib, a drug being developed by Pfizer, sharply cut the risk that advanced cancer would worsen among patients taking part in a Phase 2 study, researchers said.",positive,0.5089088678359985
2014-04-06,Guarded Optimism After Breast Cancer Drug Shows Promising Results,positive,0.5025991797447205
2014-04-21,A deal with Pfizer would have been one of the biggest ever in the pharmaceutical industry.,positive,0.4892599582672119
2014-04-21,But whether such a deal makes sense is another matter.,neutral,0.0011188853532075882
2014-04-21,"Spurning Merger Approaches, AstraZeneca Pursues Own Path",neutral,0.3114454448223114
2014-04-22,"Novartis will buy GlaxoSmithKline’s cancer drug business for as much as $16 billion, and Glaxo will buy Novartis’s vaccine business for as much as $7.1 billion.",neutral,0.10409322381019592
2014-04-22,Novartis and Glaxo Agree to Trade $20 Billion in Assets,neutral,0.3297855257987976
2014-04-22,"William A. Ackman and Valeant are bidding for Allergan, the maker of Botox.",neutral,0.05035122483968735
2014-04-22,| Novartis announced a major overhaul.,positive,0.5975944995880127
2014-04-22,| AstraZeneca says no to a deal with Pfizer.,neutral,-0.06167212128639221
2014-04-22,| Barclays is set to exit its commodities business.,negative,-0.7936596274375916
2014-04-22,Ackman’s Botox Ambitions,neutral,-0.029871396720409393
2014-04-28,"Such a move would be aimed at putting pressure on the British drug maker, which has turned down a number of informal takeover approaches.",negative,-0.4933745861053467
2014-04-28,Pfizer Move for AstraZeneca Seen,neutral,-0.28940215706825256
2014-04-28,"The Swedish drug maker rejected an increased takeover offer from the generic pharmaceutical company based in Canonsburg, Pa.",positive,0.2764732241630554
2014-04-28,Meda Again Rejects Takeover Bid by Mylan,negative,-0.5194637775421143
2014-04-28,France puts the brakes on General Electric’s bid for Alstom.,negative,-0.8667210340499878
2014-04-28,| Investors are looking for other ways to profit from the aftermath of the housing crisis.,neutral,0.09879733622074127
2014-04-28,| Pfizer continues its pursuit of AstraZeneca.,neutral,0.07131560891866684
2014-04-28,| Elizabeth Warren seeks a level playing field.,neutral,0.05946802347898483
2014-04-28,France Stalls G.E.’s Alstom Bid,neutral,-0.027840428054332733
2014-04-28,"If the British drug company AstraZeneca cannot make Pfizer go away, it can certainly make it pay, Neil Unmack of Reuters Breakingviews contends.",negative,-0.8642876148223877
2014-04-28,Why Pfizer Needs to Do More to Win AstraZeneca,positive,0.575462818145752
2014-04-29,Pfizer proposed a $99 billion acquisition of its British rival AstraZeneca that would allow it to reincorporate in Britain.,neutral,0.42589372396469116
2014-04-29,"Pfizer Proposes a Marriage With AstraZeneca, Easing Taxes in a Move to Britain",positive,0.8209452033042908
2014-04-29,Energy Future Holdings files for bankruptcy.,neutral,-0.34619057178497314
2014-04-29,| Pfizer makes a bid to move abroad with deal for AstraZeneca.,positive,0.6914196610450745
2014-04-29,| Bank of America’s $4 billion accounting error.,negative,-0.8007526397705078
2014-04-29,| France continues efforts to shield its economy.,positive,0.716304361820221
2014-04-29,A Failure in Texas,negative,-0.4629024863243103
2014-04-29,"The biggest charm of Pfizer’s offer for AstraZeneca lies in switching to a lower-tax domicile, a strategy that is sure to be duplicated, Robert Cyran writes for Reuters Breakingviews.",positive,0.6120160222053528
2014-04-29,Pfizer Most Likely Just the Tip of the Tax Sword,neutral,-0.06852658838033676
2014-04-29,"We don’t know if Pfizer is targeting a British rival because the combined firm will be more efficient or because of the tax savings, Victor Fleischer writes in his Standard Deduction column.",neutral,0.3434455096721649
2014-04-29,How Tax Laws Distort the Pfizer Deal,neutral,-0.33285069465637207
2014-05-01,"Time is working against Pfizer in its pursuit of AstraZeneca and thus it will want a friendly deal completed as quickly as possible, Christopher Hughes and Neil Unmack write for Reuters Breakingviews.",positive,0.4693801999092102
2014-05-01,Pfizer Looks for a Quick Strike on AstraZeneca,neutral,-0.28641825914382935
2014-05-02,"In a second bid for its British rival, the American drug giant Pfizer on Friday increased its offer by 7 percent.",positive,0.9067930579185486
2014-05-02,But AstraZeneca said the terms substantially undervalued the company.,negative,-0.8754659295082092
2014-05-02,AstraZeneca Rejects a Higher Bid From Pfizer,negative,-0.23123928904533386
2014-05-02,Federal authorities are looking into traders who traffic in Herbalife’s stock.,neutral,-0.2564032971858978
2014-05-02,| AstraZeneca rejected a sweetened offer by Pfizer.,negative,-0.9074119925498962
2014-05-02,| Ares is set to debut on the public market.,neutral,0.040094684809446335
2014-05-02,| K.K.R.,neutral,0.016713909804821014
2014-05-02,seeks to attract smaller investors.,neutral,0.07378694415092468
2014-05-02,Morning Agenda: Scrutiny for Traders of Herbalife,neutral,-0.005651246756315231
2014-05-02,"Pfizer’s latest offer for its rival seems cheap to shareholders who view AstraZeneca’s turnaround as well advanced, Neil Unmack writes in Reuters Breakingviews.",positive,0.719516932964325
2014-05-02,Pfizer Has Yet to Make a Compelling Bid to AstraZeneca’s Shareholders,neutral,0.12467092275619507
2014-05-05,"Pfizer announced a 15 percent drop in earnings, and again pressed its suit for its rival, AstraZeneca.",negative,-0.9605916142463684
2014-05-05,"Profit Off, Pfizer Again Aims to Lure AstraZeneca",neutral,0.13410478830337524
2014-05-06,"In presenting long-term financial estimates, AstraZeneca said it expected to achieve annual revenue of $45 billion by 2023, suggesting Pfizer’s bid undervalued the company.",negative,-0.3075809180736542
2014-05-06,AstraZeneca Makes Its Case Against Pfizer’s Takeover Bid,neutral,-0.0804373174905777
2014-05-07,"Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer.",negative,-0.5251435041427612
2014-05-07,"He bases that, in part, on having worked at Pfizer.",neutral,0.023597633466124535
2014-05-07,A Scientist’s Defense of Keeping AstraZeneca Independent,neutral,0.02828032523393631
2014-05-08,"AstraZeneca’s board would do well to evaluate whether the company’s progress will continue under Pfizer’s management, Bill George, a professor at Harvard Business School, writes in the Another View column.",positive,0.6107978224754333
2014-05-08,A Case for Rejecting Pfizer’s Bid for AstraZeneca,neutral,-0.3358802795410156
2014-05-09,Walgreen is already under pressure from hedge fund investors that want it to move across the Atlantic.,negative,-0.91936194896698
2014-05-09,Pfizer’s Plan to Go to London Spurs Other Companies to Consider Moving Abroad,neutral,0.13255912065505981
2014-05-10,"In a series of videos posted online, Pfizer’s chief executive tried to quell growing concern about the transaction.",negative,-0.7471858859062195
2014-05-10,Pfizer Continues to Defend Takeover Bid for AstraZeneca,neutral,0.23134487867355347
2014-05-12,The American pharmaceutical giant is trying to convince British lawmakers that a Pfizer-AstraZeneca combination is viable.,positive,0.5139567255973816
2014-05-12,"Pursuing AstraZeneca, Pfizer Pledges to Keep Jobs in Britain",positive,0.18425452709197998
2014-05-12,BNP Paribas and Credit Suisse ask authorities in the United States to go easy.,neutral,-0.20267035067081451
2014-05-12,| Pfizer goes online to defend its bid for AstraZeneca.,negative,-0.24960413575172424
2014-05-12,"| Timothy F. Geithner’s book, “Stress Test,” comes out today.",neutral,0.06074816733598709
2014-05-12,| Morgan Stanley is king in Silicon Valley.,neutral,0.13142675161361694
2014-05-12,BNP Paribas and Credit Suisse Seek Leniency,neutral,0.011963780969381332
2014-05-13,"The American drug maker continued its pursuit of its British competitor AstraZeneca, even as executives from both companies faced contentious questioning before Parliament over a possible takeover.",negative,-0.3578433394432068
2014-05-13,Lawmakers Mistrust a Marriage Offer Pfizer Won’t Abandon,negative,-0.8180935978889465
2014-05-13,"Investors are egging on companies to take on ever riskier transactions and are bidding up the shares of acquirers well beyond mathematical prudence, Rob Cox of Reuters Breakingviews writes.",neutral,0.24510324001312256
2014-05-13,The Brewing M.&A.,neutral,0.03526260331273079
2014-05-13,Bubble,neutral,0.04468230903148651
2014-05-13,"One lesson for companies contemplating a big merger, Steven M. Davidoff writes in the Deal Professor column: Life is not a “Mad Men” episode where ego and hubris triumph.",neutral,-0.12486986070871353
2014-05-13,"To Guide the Merger Giants, Strong Hands Are Needed",neutral,0.12651678919792175
2014-05-15,A new Reuters Breakingviews calculator shows why investors seem to believe that a $100 billion-plus acquisition by Pfizer will probably happen.,neutral,0.10752921551465988
2014-05-15,The Right Price for AstraZeneca’s Stock,neutral,0.13290049135684967
2014-05-18,The American drug giant Pfizer has made an offer worth $119 billion in what it said was a final effort to bring the British drug maker AstraZeneca to the table for deal talks.,positive,0.5835064053535461
2014-05-18,"In Last-Ditch Bid, Pfizer Offers $119 Billion for AstraZeneca",neutral,0.3442750573158264
2014-05-19,"AstraZeneca said the $119 billion offer undervalued the company, and its latest rebuff may mean the end of Pfizer’s pursuit of a merger.",negative,-0.9097456336021423
2014-05-19,AstraZeneca Snubs Pfizer Once More,negative,-0.7792486548423767
2014-05-19,"Leif Johansson, the chairman of the British pharmaceutical company AstraZeneca, explained why the board rejected the $119 billion takeover offer from the American drug maker Pfizer.",negative,-0.33791711926460266
2014-05-19,AstraZeneca’s Chairman on Pfizer’s Bid,neutral,-0.07652269303798676
2014-05-19,"Britain does not have as many takeover defenses as the United States, so it is puzzling why Pfizer did not make a full-fledged hostile bid for AstraZeneca, Steven M. Davidoff writes in the Deal Professor column.",neutral,0.020091921091079712
2014-05-19,The Curious Incident of Pfizer’s ‘Final’ Offer for AstraZeneca,neutral,0.0738760232925415
2014-05-20,"The company’s rejection of Pfizer’s latest offer disappointed some investors, while others said the deal was not in AstraZeneca’s best interest.",negative,-0.9088802337646484
2014-05-20,Pfizer’s Latest Offer Divides Some of Largest Shareholders in AstraZeneca,neutral,-0.014064949005842209
2014-05-20,"An apparent loophole in Britain’s takeover code means Pfizer could offer a higher price for AstraZeneca, even after declaring that its earlier pitch was “final,” says Christopher Hughes of Reuters Breakingviews.",positive,0.600781261920929
2014-05-20,Loophole Offers Pfizer a Risky Way Back Into a Deal,negative,-0.7590266466140747
2014-05-21,"If a merger with Pfizer really makes sense, AstraZeneca’s decision is not now or never, Christopher Hughes of Reuters Breakingviews writes.",neutral,0.03784141689538956
2014-05-21,Pfizer-AstraZeneca Talks Need a Rest and Then a Fresh Start,neutral,0.0640794113278389
2014-05-21,"The fragmented response offers a glimmer of hope to Pfizer, but AstraZeneca also contends that under British takeover law, its hands are tied unless a third part steps in with a competing bid.",negative,-0.47559115290641785
2014-05-21,AstraZeneca’s Shareholders Remain Sharply Divided Over Talks With Pfizer,negative,-0.9211636185646057
2014-05-22,"BlackRock, AstraZeneca’s largest shareholder, is said to prefer that the drug firm engage in talks with Pfizer later on rather than accept Pfizer’s most recent offer.",neutral,-0.19383352994918823
2014-05-22,BlackRock Encourages AstraZeneca to Renew Pfizer Talks at Later Date,neutral,0.12035870552062988
2014-05-26,"The European Central Bank is hosting a forum in Portugal, and American figures on consumer confidence, home prices and first-quarter growth are due.",neutral,0.08775928616523743
2014-05-26,A Banking Forum in Europe and a Raft of U.S. Economic Data,neutral,0.11065064370632172
2014-05-26,Pfizer said it “does not intend to make an offer for AstraZeneca” in the wake of AstraZeneca’s rejection of a $119 billion bid.,neutral,-0.39822420477867126
2014-05-26,Pfizer Abandons Bid for AstraZeneca,neutral,-0.2228395938873291
2014-05-27,Pfizer has abandoned its bid for AstraZeneca.,neutral,-0.3717769384384155
2014-05-27,| N.Y.U.’s trustees are tied to the university’s crisis in Abu Dhabi.,neutral,-0.15368841588497162
2014-05-27,| The S.E.C.,neutral,0.06686889380216599
2014-05-27,and private equity.,neutral,0.037958867847919464
2014-05-27,| Bill Gates has cut the pace of his own giving to his foundation.,negative,-0.8817840814590454
2014-05-27,Pfizer Lets AstraZeneca Go,neutral,-0.025602253153920174
2014-05-27,"Pfizer looks foolish for the way it handled a $119 billion bid, yet it is AstraZeneca that remains under pressure, Christopher Hughes of Reuters Breakingviews writes.",negative,-0.791589617729187
2014-05-27,The Lessons of a Drug Maker’s Failed Deal,neutral,-0.17778439819812775
2014-05-29,Marcato Capital Management said combining the Intercontinental Hotels Group’s Holiday Inn and Crowne Plaza brands with a larger hotel operator “represents a unique opportunity to reshape the global hospitality industry.”,positive,0.8931939005851746
2014-05-29,Marcato Capital Urges Intercontinental Hotels to Pursue Merger,neutral,0.25758376717567444
2014-05-29,The government says the national health service suffered losses from the drug companies’ efforts to restrict competition in ophthalmic drugs.,negative,-0.9346080422401428
2014-05-29,Italy Seeks $1.6 Billion in Damages From Roche and Novartis,negative,-0.849032461643219
2014-06-16,"Stents and sutures are not an obvious fit, Jeffrey Goldfarb and Robert Cyran of Reuters Breakingviews write, and the savings and benefits from such a merger do not appear to justify a premium of nearly $10 billion.",neutral,-0.191246896982193
2014-06-16,Medtronic-Covidien Deal Is a Marriage of Convenience,neutral,0.1012582778930664
2014-06-16,"Bill George, a former chief executive of Medtronic, opposed Pfizer’s proposed deal to acquire an overseas competitor and reincorporate abroad, but he is all in favor of his former employer making a similar deal.",negative,-0.5193509459495544
2014-06-16,Former Medtronic C.E.O.,neutral,0.008525930345058441
2014-06-16,Defends Inversion Deal,neutral,0.1252649873495102
2014-06-24,Two BNP Paribas analysts said in a research note that a sweetened offer of about $127.7 billion by Pfizer for its British rival would still make “economic sense.”,positive,0.5576595067977905
2014-06-24,Bank Analysts Say Pfizer-AstraZeneca Merger Still Makes Sense,positive,0.6102902889251709
2014-06-25,"Though AbbVie, based in Chicago, stopped short of raising its $46 billion takeover offer, its presentation and investor call on Wednesday made the case for a deal with Shire.",positive,0.6373063325881958
2014-06-25,AbbVie Signals It Will Continue to Pursue Irish Drug Maker Shire,neutral,0.3052777647972107
2014-06-26,"Auxilium Pharmaceuticals, based in Pennsylvania, agreed to acquire QLT of Canada in one of the smallest inversions in recent years.",neutral,0.39404433965682983
2014-06-26,"Auxilium, a Small Player, Buys QLT and Does an Inversion, Too",neutral,0.03753422945737839
2014-07-02,"As more companies seek to relocate by mergers — so-called inversions — it is more likely the law will change, Robert Cyran of Reuters Breakingviews writes.",neutral,0.07120176404714584
2014-07-02,The Fleeting Benefits of Overseas Corporate Marriages,neutral,0.09545384347438812
2014-07-14,"Vince Cable, the British business secretary, wants to eliminate the “wiggle room” in commitments made by foreign suitors for British companies.",negative,-0.42235732078552246
2014-07-14,A Call for Stricter Takeover Rules in Britain,neutral,-0.0887363851070404
2014-07-15,"The pharmaceutical company is hoping to bring a new acronym into the vernacular with FOGO, or fear of getting old.",neutral,0.08227165043354034
2014-07-15,Pfizer to Inject Youth Into the Aging Process,neutral,-0.05649372935295105
2014-07-24,"Allergan, the target of a $52 billion hostile bid, is linking stock and option grants to lofty profit goals.",positive,0.6578351855278015
2014-07-24,"It is a bold tactic that should become a norm in M.&A., contends Robert Cyran of Reuters Breakingviews.",positive,0.6356797218322754
2014-07-24,Botox Maker’s Bosses Put Money Where Their Mouths Are,negative,-0.5603995323181152
2014-07-25,"How AbbVie came to win Shire demonstrates that even in the middle of a new boom in mergers and acquisitions, a hefty premium is no guarantee of success.",positive,0.6805058717727661
2014-07-25,"To Woo Drug Maker Shire, AbbVie Trod Cautiously in Tax Inversion Bid",positive,0.4273138642311096
2014-07-30,"The British drug maker said it would initially pay $875 million for the rights to the drugs, and up to $1.22 billion more if development and sales milestones are met.",positive,0.6743987202644348
2014-07-30,AstraZeneca to Pay Almirall Up to $2.1 Billion for Respiratory Drugs,neutral,0.18634547293186188
2014-09-02,Public pension funds have major stakes in American companies moving overseas to cut their tax bills.,neutral,0.042774081230163574
2014-09-02,"But they are saying little about the strategy, which could hurt the nation’s tax base.",negative,-0.8298264741897583
2014-09-02,Public Pension Funds Stay Mum on Corporate Expats,neutral,-0.21372202038764954
2014-09-23,Some American-led transactions may survive on strategic logic.,neutral,0.25052589178085327
2014-09-23,"But pure tax-avoiding combinations look tricky, Neil Unmack and Robert Cyran of Reuters Breakingviews write.",neutral,-0.0016821026802062988
2014-09-23,U.S. Curbs on Inversions May Deter Some Pharmaceutical Deals,negative,-0.9492151141166687
2014-10-04,"Companies like Allergan, Valeant, Salix, Actavis and Medtronic are riding a wave of cheap debt and pent-up demand in a slew of recent acquisitions or attempted acquisitions.",neutral,0.12864084541797638
2014-10-04,A Scramble to Acquire for Drug Companies,neutral,-0.2916083037853241
2014-10-14,"Already, 2014 ranks as the busiest year for failed mergers since 2008, data from Thomson Reuters shows.",negative,-0.6878207325935364
2014-10-14,An Ill-Fated Bid for T-Mobile US is the Latest in a Year of Failed Deals,negative,-0.89980548620224
2014-10-15,Shares of Shire tumble in London trading amid fears that a $54 billion deal — the biggest takeover this year — is in trouble.,negative,-0.9558799862861633
2014-10-15,Shire Urges AbbVie to Pursue Merger Despite New Inversion Rules,neutral,0.17677196860313416
2014-10-15,"The American drug company’s retreat, writes Neil Unmack of Reuters Breakingviews, will make it difficult for the board of any European company to approve an inversion bid in the future.",negative,-0.9324026703834534
2014-10-15,AbbVie’s U-Turn Shows Shire Deal Was Driven by Taxes,neutral,0.10558541119098663
2014-10-29,"The strain, known as serogroup B meningitis, infected students at Princeton and the University of California, Santa Barbara last year.",negative,-0.835170567035675
2014-10-29,F.D.A.,neutral,0.04497655853629112
2014-10-29,"Approves Pfizer’s Trumenba, a Vaccine for a Rare Meningitis",positive,0.7943848371505737
2014-11-11,The activist investor William A. Ackman has acquired an 8.5 percent economic interest in the former animal health arm of Pfizer.,neutral,0.047841332852840424
2014-11-11,"Zoetis, an Animal Health Company, Says Ackman Has Taken a Stake",neutral,-0.032929182052612305
2014-11-13,Groups including the Bill & Melinda Gates Foundation aim to help bring an easier-to-inject form of Depo-Provera to 69 countries.,positive,0.4972996413707733
2014-11-13,Pfizer and Aid Groups Team Up on Contraceptive for Developing World,positive,0.6838302612304688
2014-11-17,"The alliance between the American and German companies is expected to strengthen Merck’s oncology business in several important markets, including the United States.",positive,0.9330943822860718
2014-11-17,Pfizer to Pay up to $2.9 Billion in Cancer Drug Deal With Merck of Germany,positive,0.6592859625816345
2014-12-08,"The deal will give Merck, the second-largest American drug maker after Pfizer, control of the largest antibiotics company, and deepen its ties with hospitals.",positive,0.8312380909919739
2014-12-08,"Merck in $8.4 Billion Deal for Cubist, Big Maker of Antibiotics",neutral,0.4630807042121887
2015-01-09,"In search of an alternative to hearing aids or implants, some report success in early trials for drugs to improve hearing or silence tinnitus.",positive,0.668166995048523
2015-01-09,"From Vertigo to Tinnitus, Ear Ailments Are New Focus for Drugs",neutral,0.0475340411067009
2015-02-05,"In its offer to buy Hospira, Pfizer is paying richly for what it believes will be a lucrative source of future revenue, drugs known as biosimilars.",neutral,0.28041180968284607
2015-02-05,Pfizer Bets $15 Billion on New Class of Generic Drugs,neutral,0.17281609773635864
2015-02-05,"The pharmaceutical giant’s $15 billion purchase of Hospira should bolster Pfizer’s own generics unit – and open the way for spinning it off, says Robert Cyran of Reuters Breakingviews.",positive,0.9138940572738647
2015-02-05,A Deal That Could Reverse Pfizer’s History of Value-Destroying Acquisitions,positive,0.7510889172554016
2015-02-05,"In what might be called “transaction Thursday,” some $25.7 billion of deals were recorded, according to Thomson Reuters, including Pfizer’s purchase of Hospira and BT’s acquisition of the mobile carrier EE.",neutral,0.06798646599054337
2015-02-05,"Pfizer Deal and Other Mergers Show a Case of the Mondays, on a Thursday",neutral,0.03392178565263748
2015-02-06,RadioShack files for bankruptcy.,negative,-0.5100437998771667
2015-02-06,| Ally Financial is looking to ramp up performance.,positive,0.9192511439323425
2015-02-06,| Pfizer makes a big bet on a new class of generics.,neutral,0.4630398452281952
2015-02-06,| Dysfunction continues at GFI.,negative,-0.930751621723175
2015-02-06,Morning Agenda: RadioShack’s Bankruptcy Filing,neutral,-0.1784852147102356
2015-03-20,"The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials.",positive,0.7160926461219788
2015-03-20,Biogen Reports Its Alzheimer’s Drug Sharply Slowed Cognitive Decline,negative,-0.8472428917884827
2015-04-27,"Swedish Orphan Biovitrum, which makes the ReFacto AF treatment for hemophilia for Pfizer, received a preliminary offer from an undisclosed suitor.",neutral,0.36816003918647766
2015-04-27,"Sobi, Swedish Maker of Drugs for Rare Diseases, Receives Takeover Bid",neutral,0.1180916354060173
2015-06-02,"If companies are going to fight activist investors who call for breakups or spinoffs, they should also be more honest about downsides of mergers.",neutral,0.3135814070701599
2015-06-02,"Breaking Up Companies Creates Extensive Costs, Too",neutral,-0.4175165593624115
2015-07-01,"Four executives of leading health care organizations are members of the board of the U.S. Chamber of Commerce, which is engaged in a worldwide campaign to thwart antismoking laws.",neutral,-0.015548545867204666
2015-07-01,U.S. Chamber Fights Smoking Laws While Hospitals and Insurers Sit on Its Board,neutral,-0.253103107213974
2015-10-14,The Pfizer chemist helped create the antidepressant that has been used to treat more than 100 million people and has generated sales of more than $3 billion.,positive,0.5367705225944519
2015-10-14,"Kenneth Koe, an Inventor Behind Zoloft, Dies at 90",neutral,-0.3264678716659546
2015-10-29,"Pfizer, one of America’s oldest drug makers, is again looking to renounce its corporate citizenship by buying a foreign rival.",neutral,0.17589981853961945
2015-10-29,Pfizer Bid for Allergan Has Its Eyes on Ireland,neutral,-0.19303588569164276
2015-10-29,Allergan can hold out for a good price.,neutral,0.06806016713380814
2015-10-29,"But if Pfizer puts up a premium of more than 25 percent, it will risk paying away the benefits of a deal.",negative,-0.8417611122131348
2015-10-29,Pfizer Faces Challenges in Pursuing Deal for a Lower Tax Rate,neutral,-0.2860858142375946
2015-10-29,"Cheap capital, low interest rates and the challenges posed by the Affordable Care Act are driving health companies of all kinds, not just hospitals, to combine.",positive,0.6595954895019531
2015-10-29,Health Care Companies in Merger Frenzy,neutral,-0.23491427302360535
2015-11-04,"In response Mylan’s move to the Netherlands, the Securities and Exchange Commission now requires shareholder votes for each governance change from such deals.",neutral,0.05038713291287422
2015-11-04,Regulators Unbundle Some Attractions of Mergers,neutral,-0.06420101225376129
2015-11-06,The transaction is expected to improve the British drug maker’s pipeline of treatments for cardiovascular and metabolic diseases.,positive,0.923375129699707
2015-11-06,AstraZeneca Agrees to Buy ZS Pharma for $2.7 Billion,positive,0.5356419682502747
2015-11-19,A merger would create a drug giant with nearly $53 billion in annual sales and give Pfizer a long-sought foreign headquarters for tax purposes.,positive,0.6073663234710693
2015-11-19,Pfizer and Allergan Said to Be Near Merger for Up to $150 Billion,neutral,0.07908402383327484
2015-11-19,"Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox.",positive,0.5953168272972107
2015-11-19,But Allergan would accrue nearly all of the upside.,neutral,0.019114108756184578
2015-11-19,High Risk and Low Benefit in Pfizer’s Pursuit of Allergan,neutral,-0.02202308550477028
2015-11-22,"The deal, to be announced Monday, would create a huge new pharmaceutical giant and could potentially help Pfizer lower its American tax rate.",positive,0.8160238265991211
2015-11-22,Pfizer and Allergan Reach $150 Billion Merger Deal,neutral,0.4583331346511841
2015-11-23,"The agreement would be the latest, and largest, aimed at helping an American company lower its taxes by reincorporating overseas, a tactic known as corporate inversion.",neutral,0.4766503870487213
2015-11-23,Pfizer Chief Defends Merger With Allergan as Good for U.S.,positive,0.5733944177627563
2015-11-23,"The deal will bring hefty tax and cost savings worth slightly more than the $30 billion premium being offered, but the structure will upset lawmakers.",negative,-0.20765423774719238
2015-11-23,"Pfizer’s Huge Deal Could Work, but With Adverse Effects",neutral,0.016057997941970825
2015-11-23,"While not technically structured as an inversion, the huge drug merger spurs calls for change.",positive,0.5050630569458008
2015-11-23,Pfizer Deal Stokes Washington Concerns Over Tax Policy,negative,-0.8372281193733215
2015-11-23,"With an equity value of $152 billion, the merger is the largest since the heady days of 2000.",positive,0.5998141169548035
2015-11-23,How the Pfizer-Allergan Deal Ranks,neutral,0.03657025471329689
2015-11-24,The blockbuster pharmaceutical merger has put new pressure on Congress and the White House to overhaul the corporate tax code.,negative,-0.5180551409721375
2015-11-24,Pfizer-Allergan Merger Reignites Tax Reform Discussion,neutral,0.2024829238653183
2015-11-24,"The United States approach has been a failure, and a $152 billion drug merger could nudge tax-writing committees in Washington into action.",negative,-0.9360020160675049
2015-11-24,Why Pfizer’s Deal May Change the System of Taxing Multinationals,neutral,0.0835876613855362
2015-11-24,"The deal with Allergan will cut taxes and add solid assets, but it is also prompting Pfizer to defer a decision on splitting up until 2018.",positive,0.8559873700141907
2015-11-24,Pfizer’s Desire to Split Has Faded,neutral,-0.0022888444364070892
2015-11-24,The two companies have outlined the various termination fees they will pay each other in the event the $152 billion merger collapses.,neutral,-0.04682007431983948
2015-11-24,Pfizer and Allergan Deal Comes With an Extensive Prenup,neutral,0.09199173748493195
2015-11-25,Recent deals show that normally sober-minded business executives seem to have thrown over sound decision-making for flights of fancy.,neutral,-0.056401390582323074
2015-11-25,Pfizer-Allergan Merger Is Latest Sign of Deal Makers’ Silly Pills,neutral,-0.014452725648880005
2015-11-25,An offshore tax address means there’s no reason to keep over $60 billion of cash on its balance sheet.,negative,-0.556158185005188
2015-11-25,That’s a lot of financial firepower to buy back shares and fuel more acquisitions.,positive,0.5847821831703186
2015-11-25,How Allergan Deal Will Rebuild Pfizer’s War Chest,neutral,0.2098025530576706
2015-11-25,"The Pfizer-Allergan merger has been criticized because of a planned headquarters move to Ireland, but such strategies are not necessary to avoid taxes.",negative,-0.7314837574958801
2015-11-25,Pfizer Didn’t Need an Inversion to Avoid Paying U.S. Taxes,neutral,-0.0409732386469841
2015-12-01,"Pfizer, which plans to enjoy a lower tax rate in Ireland after a merger with Allergan, has long employed various tax avoidance strategies.",neutral,0.024438844993710518
2015-12-01,Pfizer’s Long War on Taxation,neutral,-0.11434414237737656
2015-12-01,That this high-water mark is justified by its tax workaround is a sign that the two-year boom of extraordinary corporate deals is reaching its conclusion.,positive,0.8219683170318604
2015-12-01,Pfizer’s Deal for Allergan Is a Dubious Milestone,neutral,0.05821296572685242
2015-12-15,The exchange of business units would make Sanofi one of the world’s largest manufacturers of nonprescription medicines.,positive,0.8033310770988464
2015-12-15,European Drug Makers Sanofi and Boehringer Ingelheim in Talks,neutral,-0.06459546834230423
2015-12-17,"The deal would be the latest by a pharmaceutical company in what has been a record year for mergers and acquisitions, driven in part by transactions in the health care sector.",neutral,0.4601094424724579
2015-12-17,AstraZeneca to Acquire Majority Stake in Acerta Pharma,neutral,0.05377441272139549
2015-12-18,The British drug maker plans to acquire treatments at various stages of research in a deal with Bristol-Myers Squibb of New York that could be worth $1.46 billion.,neutral,0.20989719033241272
2015-12-18,GlaxoSmithKline to Buy Raft of H.I.V.,neutral,0.09493069350719452
2015-12-18,Drugs in Development,neutral,0.05445354804396629
2015-12-22,"The merger market is on track for a $4 trillion-plus year, and deal makers are no doubt celebrating, but this is also a time for reflection.",neutral,0.2518458664417267
2015-12-22,"In a Record Year for Deals, Success and a Few Missteps",neutral,-0.02769830822944641
2016-01-05,"The insulin, called Afrezza, has had poor sales since being approved by the F.D.A.",negative,-0.9572476744651794
2016-01-05,in 2014.,neutral,0.07005567848682404
2016-01-05,"Shares in its maker, MannKind, fell 48 percent.",negative,-0.959272027015686
2016-01-05,Sanofi Ends Marketing Deal With Developer of Inhaled Insulin,neutral,0.010313421487808228
2016-01-11,Some pharmaceutical companies will form the National Immunotherapy Coalition to rapidly test various combinations of promising new types of cancer drugs.,neutral,0.1960538923740387
2016-01-11,Drug Companies to Try a Unified Front Against Cancer,neutral,-0.19005906581878662
2016-01-13,"When hemophiliacs make their living by selling lucrative hemophilia drugs, patient advocates say it creates a dangerous conflict of interest.",negative,-0.8534726500511169
2016-01-13,Hemophilia Patient or Drug Seller?,neutral,-0.1713441014289856
2016-01-13,Dual Role Creates Ethical Quandary,neutral,0.04306764155626297
2016-01-26,"Johnson Controls is just the latest corporation to flee America for greener, lower-tax pastures.",neutral,0.007050316780805588
2016-01-26,"And until lawmakers reform the tax code, the exodus will continue.",neutral,-0.3675215244293213
2016-01-26,A Tidal Wave of Corporate Migrants Seeking (Tax) Shelter,neutral,-0.24634869396686554
2016-02-10,The bigger benefit to corporations fleeing American tax bills — and the bigger loss to American taxpayers — is a maneuver called earnings stripping.,negative,-0.7056983113288879
2016-02-10,Corporate Inversions Aren’t the Half of It,neutral,-0.12131150811910629
2016-02-19,"If Burger King and Pfizer can lower their tax rates with inversions, why can’t I?",neutral,0.17103710770606995
2016-02-19,Just Send the Tax Bill to My Personal Irish Subsidiary,neutral,-0.018879957497119904
2016-04-05,The new rules take particular aim at companies that have completed multiple acquisitions of American companies in a short period.,neutral,0.03796989098191261
2016-04-05,U.S. Moves to Thwart Use of Foreign Inversions as Tax Dodge,negative,-0.5839329361915588
2016-04-05,"The proposed regulations are more aggressive and expansive than the administration’s earlier volleys, but they may face a legal challenge.",neutral,0.06896007061004639
2016-04-05,"On Inversions, the Treasury Department Drops the Gloves",negative,-0.7363245487213135
2016-04-05,"The broader reach of regulations, intended to keep companies from cutting deals to move income overseas, appears to have caught many by surprise.",negative,-0.7229183912277222
2016-04-05,Pfizer and Allergan Are Said to End Merger as Tax Rules Tighten,neutral,-0.19469812512397766
2016-04-06,"The company has been growing steadily, but investors are certain to start agitating again to complete a bold move in order to push growth higher.",positive,0.8959176540374756
2016-04-06,Pfizer Faces Limited Options After Its Dead Deal With Allergan,neutral,-0.2833382189273834
2016-04-06,"Now that the merger between the pharmaceutical giants is dead, their bankers will receive about 10 percent of their fees, according to estimates.",neutral,-0.07843507826328278
2016-04-06,Pfizer and Allergan Advisers Lose Out on $200 Million in Fees,negative,-0.9365631341934204
2016-04-06,"In the abandoned merger with Allergan, lawmakers, the Treasury Department and Pfizer itself bear some responsibility.",neutral,-0.033295631408691406
2016-04-06,Finger-Pointing Abounds in Failed Pfizer Deal,negative,-0.619217574596405
2016-04-07,"The Obama administration took on two possible deals this week, and claimed a victory with one.",positive,0.6822591423988342
2016-04-07,Megamergers Face Deterrents in the United States,negative,-0.7772247791290283
2016-04-07,"The government’s crackdown on inversions and two lawsuits it filed this week offer some things for advisers, companies and shareholders to think about.",neutral,-0.0035720281302928925
2016-04-07,Lessons in a Busy Week of Deal Busting,neutral,0.022462621331214905
2016-04-14,"Companies are abandoning the biggest mergers, largely out of concern over how the government might react in an election year.",negative,-0.9222552180290222
2016-04-14,The Winds From Washington Chill Wall Street’s Deal Making,negative,-0.6967763900756836
2016-05-05,"As the drug-giant weighs its options, setting a strategy would be better than keeping all doors open.",neutral,0.05853452533483505
2016-05-05,Pfizer Needs Clearer Goals,neutral,0.11824795603752136
2016-05-10,The recent actions of Zoetis and Allergan suggest a more subdued approach to deals.,neutral,-0.11839526146650314
2016-05-10,Change Is in the Air for Pharmaceutical Mergers,neutral,0.06604282557964325
2016-05-12,"Since the beginning of January, $400 billion worth of corporate mergers have fallen apart in the United States, creating anxiety in those who bet on them.",negative,-0.9455683827400208
2016-05-12,Hedge Funds Look for Hard Hats in a Year of Collapsing Mergers,negative,-0.38639602065086365
2016-05-16,"After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions.",neutral,0.046139150857925415
2016-05-16,Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion,neutral,0.013871666975319386
2016-05-16,"The more important question for shareholders, though, is whether Pfizer’s chief executive, Ian C. Read, will break up Pfizer.",neutral,-0.004981314763426781
2016-05-16,Pfizer Could Get Its Money’s Worth Out of Anacor Deal,neutral,0.06015042960643768
2016-05-31,"Months ago, Mr. Icahn criticized Pfizer’s proposed takeover of Allergan; now he is buying part of the company.",negative,-0.5252658128738403
2016-05-31,Carl Icahn Takes Stake in Allergan,neutral,0.026964407414197922
2016-07-07,"The Treasury Department wants to curb a practice called earnings stripping, but its efforts could hurt normal funding practices.",negative,-0.8948721289634705
2016-07-07,Plan to Curb Tax-Inversion Deals Could Go Too Far,negative,-0.8298569917678833
2016-08-04,The Chamber is leading a legal fight in Texas to overturn Treasury rules aimed at curbing mergers done for tax reasons.,negative,-0.6274228692054749
2016-08-04,Tax-Avoiding Mergers Find Champion in U.S. Chamber of Commerce,neutral,0.295762300491333
2016-08-22,"If you pay rent to a property management company with the aim of eventually owning the place, are you a renter or a homeowner?",neutral,-0.01771596632897854
2016-08-22,Some companies are blurring that line.,negative,-0.7885797619819641
2016-08-22,Morning Agenda: Tenants Struggle in Win-Win Contracts for Landlords,negative,-0.9129917621612549
2016-08-22,"The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.",neutral,0.08776991069316864
2016-08-22,Pfizer to Buy Cancer Drug Maker in $14 Billion Deal,neutral,0.06033102422952652
2016-08-22,A heated auction and back-of-the-envelope math hint that the buyer is overpaying.,neutral,0.06212851405143738
2016-08-22,The Flaws in Pfizer’s Plan to Acquire Medivation,negative,-0.5926258563995361
2016-08-23,"Collapsing oil prices are one thing, but oil refineries must now contend with the soaring cost of renewable energy credits.",neutral,0.055129870772361755
2016-08-23,"Morning Agenda: Prices of Ethanol Credits Surge, Hurting Oil Refiners",negative,-0.9611653089523315
2016-09-26,"Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up.",negative,-0.47247326374053955
2016-09-26,"Pfizer Remains Whole, but the Option to Split Could Return",neutral,-0.0003813914954662323
2016-10-13,Part of the Treasury’s goal was to clamp down on earnings stripping.,neutral,0.05682459473609924
2016-10-13,But many multinationals with no history of inversions were affected by the rules as well.,negative,-0.8506383299827576
2016-10-13,Companies Hurt by Treasury Crackdown Win Exemptions,negative,-0.23781204223632812
2016-11-06,"Proposition 56 would tax e-cigarettes in the state for the first time, despite evidence suggesting e-cigarettes are less harmful and may help people quit smoking.",neutral,0.4419529438018799
2016-11-06,Who Wins if California Voters Tax E-Cigarettes?,neutral,0.028595559298992157
2016-12-15,MSCI’s social index business grows as big pensions and other investors pour money into funds that focus on more than just corporate balance sheets.,positive,0.5766652226448059
2016-12-15,Investors Sharpen Focus on Social and Environmental Risks to Stocks,neutral,0.05588191747665405
2016-12-26,"Big takeovers by the likes of the pharmaceutical giant Pfizer, the Oreos maker Mondelez and the office supply retailer Staples were all consigned to the scrap heap.",negative,-0.6331667900085449
2016-12-26,2016 Was a Year for Undoing Major Deals,negative,-0.4712141156196594
